Email updates

Keep up to date with the latest news and content from BMC Endocrine Disorders and BioMed Central.

Open Access Research article

Insulin use and persistence in patients with type 2 diabetes adding mealtime insulin to a basal regimen: a retrospective database analysis

Machaon M Bonafede1*, Anupama Kalsekar26, Manjiri Pawaskar3, Kimberly M Ruiz4, Amelito M Torres45, Karen R Kelly6 and Suellen M Curkendall4

Author Affiliations

1 Outcomes Research, Thomson Reuters Inc, 37 Lowell Street, Andover MA 01810, USA

2 Current Address: Global Health Economics and Outcomes Research, Bristol Myers Squibb, PO Box 4000, Province Line Road, Princeton, NJ 08543, USA

3 Global Health Outcomes: Endocrine/Obesity/Metabolism, Eli Lilly and Company, Lilly Technology Center, Indianapolis, IN 46285, USA

4 Outcomes Research, Thomson Reuters Inc, 4301 Connecticut Ave NW, Suite 330. Washington DC 20008, USA

5 Current Address: Healthcare Research and Analytics, GE Healthcare, 101 Cargenie Center, Princeton, NJ 08540, USA

6 Diabetes and Devices Platform, Eli Lilly and Company, Lilly Technology Center, Indianapolis, IN 46202, USA

For all author emails, please log on.

BMC Endocrine Disorders 2011, 11:3  doi:10.1186/1472-6823-11-3

Published: 12 January 2011



The objective of this study was to characterize insulin use and examine factors associated with persistence to mealtime insulin among patients with type 2 diabetes (T2D) on stable basal insulin therapy initiating mealtime insulin therapy.


Insulin use among patients with T2D initiating mealtime insulin was investigated using Thomson Reuters MarketScan® research databases from July 2001 through September 2006. The first mealtime insulin claim preceded by 6 months with 2 claims for basal insulin was used as the index event. A total of 21 months of continuous health plan enrollment was required. Patients were required to have a second mealtime insulin claim during the 12-month follow-up period. Persistence measure 1 defined non-persistence as the presence of a 90-day gap in mealtime insulin claims, effective the date of the last claim prior to the gap. Persistence measure 2 required 1 claim per quarter to be persistent. Risk factors for non-persistence were assessed using logistic regression.


Patients initiating mealtime insulin (n = 4752; 51% male, mean age = 60.3 years) primarily used vial/syringe (87%) and insulin analogs (60%). Patients filled a median of 2, 3, and 4 mealtime insulin claims at 3, 6, and 12 months, respectively, with a median time of 76 days between refills. According to measure 1, persistence to mealtime insulin was 40.7%, 30.2%, and 19.1% at 3, 6, and 12 months, respectively. Results for measure 2 were considerably higher: 74.3%, 55.3%, and 42.2% of patients were persistent at 3, 6, and 12 months, respectively. Initiating mealtime insulin with human insulin was a risk factor for non-persistence by both measures (OR < 0.80, p < 0.01). Additional predictors of non-persistence at 12 months included elderly age, increased insulin copayment, mental health comorbidity, and polypharmacy (p < 0.05 for all).


Mealtime insulin use and persistence were both considerably lower than expected, and were significantly lower for human insulin compared to analogs.